Delving into the Latest Updates on Trilostane with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abetafen, Modrastane, Modrefen

+ [9]

Target

ERβ

Mechanism

ERβ modulators(Estrogen receptor beta modulators)

Therapeutic Areas

Endocrinology and Metabolic DiseaseOther Diseases

Active Indication

Cushing SyndromeHyperaldosteronism

Inactive Indication

Adenocarcinoma of prostateCastration-Resistant Prostatic CancerProstatic Cancer

Originator Organization

Sanofi

Active Organization

Mochida Pharmaceutical Co., Ltd.

Inactive Organization

Genzyme Corp.

Bioenvision, Inc.

Drug Highest PhaseApproved

First Approval Date

US (31 Dec 1984),

Prostatic Cancer

Regulation-

Login to view timeline

Structure

Molecular FormulaC20H27NO3

InChIKeyKVJXBPDAXMEYOA-CXANFOAXSA-N

CAS Registry13647-35-3

In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time. During medical abortion the endometrial shedding is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or require surgical intervention. In medical abortion a progesterone antagonist is used as treatment but the estrogen levels are not targeted. The investigators wish to explore whether addition of letrozole or trilostane which target estrogen levels can lead to a more effective shedding of the endometrial lining.

Start Date01 May 2012

Sponsor / Collaborator

Karolinska Institutet

[+2]

EUCTR2004-004533-34-GB / Not yet recruitingPhase 4

A Phase IV Non-randomised Study of Modrenal® (Trilostane) in Post-menopausal Women with Advanced, Oestrogen Receptor Positive Breast Cancer for whom Prior Endocrine Therapies have Failed, One of which was an Aromatase Inhibitor

Start Date19 May 2005

Sponsor / Collaborator

Bioenvision, Inc.

NCT00181597 / CompletedPhase 2

A Phase II Study of Trilostane for Androgen-Independent Prostate Cancer

The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.

Start Date01 Mar 2004

Sponsor / Collaborator

Genzyme Corp.

100 Clinical Results associated with Trilostane

Login to view more data

100 Translational Medicine associated with Trilostane

Login to view more data

100 Patents (Medical) associated with Trilostane

Login to view more data

469

Literatures (Medical) associated with Trilostane

01 Jan 2025·Journal of Ethnopharmacology

Multi-omics and bioinformatics for the investigation of therapeutic mechanism of roucongrong pill against postmenopausal osteoporosis

Article

Author: Guo, Junpeng ; Li, Chenhao ; Su, Xin ; Jiang, Tao ; Meng, Qianting ; Hu, Wanli ; Guo, Jiurui ; Zhu, Xiaojuan ; Song, Wu ; Du, Xingchen ; Li, Yufen

ETHNOPHARMACOLOGICAL RELEVANCEThe Roucongrong Pill (RCRP), originating from the historical General Medical Collection of Royal Benevolence, is frequently used to treat postmenopausal osteoporosis (PMOP). Despite its prevalent application, the specific anti-osteoporotic mechanisms of RCRP remain to be elucidated.AIM OF THE STUDYThis study aims to elucidate the therapeutic mechanism of RCRP in the context of ovariectomy (OVX)-induced PMOP in rats. By employing an integrative approach, the research combines medicinal chemistry, gut microbiota (GM) profiling, metabolomics, MetOrigin traceability, network pharmacology, molecular docking, and molecular dynamics simulations to deliver a comprehensive analysis.MATERIALS AND METHODSSprague-Dawley (SD) rats underwent bilateral OVX to establish a PMOP model. The therapeutic efficacy of RCRP was evaluated through bone metrics (BMD, bone strength, BV/TV, Tb.Sp), hematoxylin and eosin (H&E) histological assessment, and bone metabolism markers (OPG, BALP, TRACP-5b, β-CTX, RANKL). Fecal metabolomics and 16S rDNA sequencing were employed to assess the influence of RCRP on GM and metabolite profiles. Furthermore, MetOrigin facilitated the traceability analysis of relevant metabolites. Molecular docking identified potential RCRP compounds with anti-PMOP activity, while their stability and protein interactions were assessed through molecular dynamics simulations. Network pharmacology further confirms the targets of action.RESULTSRCRP alleviated PMOP in rats, enhancing bone strength, cortical and trabecular BMD, BV/TV, and serum OPG levels, while reducing Tb.Sp, serum BALP, TRACP-5b, β-CTX, and RANKL concentrations. A total of twenty-six distinct metabolites were identified, of which ten-tribufos, sulfoacetic acid, betamethasone dipropionate, 9-oxooctadeca-10,12,15-trienoic acid, menatetrenone, piperlongumine, maltopentaose, enol-phenylpyruvate, catechol, pentaacetate, and (+)-2-methylpropanoic acid-exhibited correlations with six GM species: Turicibacter, Roseburia, Colidextribacter, Helicobacter, Odoribacter, and Lachnoclostridium, as determined by Spearman's correlation analysis. Notably, MetOrigin revealed the microbial metabolism of taurine and hypotaurine, along with host-specific steroid hormone synthesis. Computational docking studies demonstrated robust interactions between five RCRP-derived steroids (hydroxyecdysone, corticosterone, trilostane, 5α-androstan-3,6,17-trione, and cortisol) and key enzymes (estradiol 17α-dehydrogenase and UDP-glucuronosyltransferase), suggesting a potential enhancement of therapeutic efficacy against PMOP. Furthermore, molecular dynamics simulations indicated stable interactions between hydroxyecdysone and two proteins, with binding free energies of -67.427 kJ/mol and -156.948 kJ/mol, respectively. Through network pharmacology and molecular docking approaches, potential targets of these metabolites were identified, including estrogen receptors ESR1 and ESR2, dual specificity phosphatase 6 (DUSP6), sex hormone-binding globulin (SHBG), prostaglandin E receptor 4 (PTGER4), cannabinoid receptor 2 (CNR2), cathepsin K (CTSK), and androgen receptor (AR).CONCLUSIONSRCRP effectively mitigates OVX-induced bone loss in PMOP rats by modulating GM and associated metabolites, along with their potential targets and key metabolic pathways, including taurine and hypotaurine metabolism, as well as steroid hormone biosynthesis. These findings offer new insights into the therapeutic mechanisms by which RCRP may alleviate PMOP.

01 Oct 2024·Domestic Animal Endocrinology

Association between post-ACTH cortisol and trilostane dosage in dogs with pituitary-dependent hypercortisolism

Article

Author: Vargas, Alessandra Martins ; Borin-Crivellenti, Sofia ; Reis, Natani Silva ; Gouvêa, Fernanda Nastri ; Crivellenti, Leandro Zuccolotto ; Guimarães, Ednaldo Carvalho ; Pennacchi, Caio Santos ; de Cerqueira, Hévila Dutra Barbosa ; Branco, Luana de Oliveira

Trilostane is the current treatment of choice for managing pituitary-dependent hypercortisolism (PDH) in dogs. While prescribing higher initial doses may elevate the risk of iatrogenic hypocortisolism, opting for more conservative approach could result in delayed disease control, since most individuals end up requiring dosage increases. The adrenocorticotrophin stimulation test (ACTHst), a widely recognized hormonal test for assessing adrenal function, is an essential tool for monitoring the pharmacological treatment of canine hypercortisolism (CH) that can also be used for diagnostic purposes. The aim of this study was to investigate the relationship between post-ACTH cortisol (cpACTH) at PDH diagnosis and the required trilostane dose for sign control and endogenous cortisol regulation in dogs, considering a hypothesis that higher serum cpACTH concentration would necessitate a higher trilostane dosage for disease management. Data for 43 dogs with PDH had their diagnostic cpACTH recorded and correlated to the trilostane dosage necessary to control clinical signs and achieve satisfactory cortisol levels (ideally 2-7 μg/dL). The odds ratio (p=0.042) suggests that dogs with cpACTH ≥ 27 μg/dL at diagnosis are 96% more likely to need a higher trilostane dosage for achieving satisfactory control of PDH. Thus, cpACTH was found to be associated with the final trilostane dose for controlling PDH in dogs.

01 Sep 2024·Veterinary Medicine and Science

Successful laparotomic ethanol ablation for an adrenal tumour in a dog

Article

Author: Furusato, Shimon ; Tsuyama, Yu ; Tamura, Yu ; Kondo, Eriko

AbstractAdrenalectomy is the gold standard for canine adrenal tumours, but not always recommended due to patient age, underlying conditions and perioperative mortality. Ethanol ablation is an alternative in human medicine for poor surgical candidates. A 13‐year‐old neutered female toy‐poodle with hypercortisolism presented with severe haematuria. Ultrasonography revealed left adrenal and right kidney tumours. Due to high surgical risk, simultaneous laparotomic right nephroureterectomy and ethanol ablation of the left adrenal tumour were performed. Post‐ethanol injection complications included transient hypertension and arrhythmia, which resolved spontaneously. The adrenal tumour size decreased within 2.5 months, and cortisol levels normalised within 8 days, remaining stable for 12 months. No hypercortisolism signs were observed without trilostane until death from renal insufficiency. Autopsy showed that the ablated left adrenal gland was an adrenocortical tumour and had shrunk. Ethanol ablation may be a feasible alternative to adrenalectomy for high‐risk canine patients.

100 Deals associated with Trilostane

Login to view more data